Paper Review Records
All Paper Review Records
30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts
Mara Memoli; Stefania Leone; Vincenzo Fotticchia; Simona Avilia; Novella Pugliese; Catello Califano; Maria Di Perna; Danilo De Novellis; Antonella Malandrini; Bianca Serio; Camilla Frieri; Giuseppe Gaeta; Chiara Masucci; Alessandro D'Ambrosio; Paola Della Cioppa; Giuseppe Cerciello; Tiziana Izzo; Mario Annunziata; Annamaria Maddaloni; Cono Quagliano; Giorgia Battipaglia; Marco Picardi; Francesco Grimaldi; Fabrizio PaneShow moreShow less
1. Department of Clinical Medicine and Surgery Hematology Division University of Naples Federico II Naples Italy; 2. Hematopoietic Stem Cell Transplantation Unit Azienda Ospedaliera A. Cardarelli Naples Italy; 3. Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy; 4. Division of Onco‐Hematology Plesso Ospedaliero Andrea Tortora Pagani Italy; 5. Department of Medicine Surgery and Dentistry Scuola Medica Salernitana University of Salerno Baronissi Italy; 6. Hematology and Transplant Center University Hospital San Giovanni Di Dio e Ruggi d’Aragona Salerno Italy; 7. Hematology and Bone Marrow Transplant Unit AORN S. Giuseppe Moscati Avellino Italy; 8. AORN S.Anna e S. Sebastiano Caserta Italy; 9. Hematology Unit Azienda Sanitaria Locale Napoli 1 Centro Naples Italy; 10. Hematology San Pio Hospital of Benevento Benevento Italy; 11. Division of Hematology AORN Cardarelli Naples Italy; 12. Section of Hematology Ospedale S. Giuliano di Giugliano Naples ItalyShow moreShow less
Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases
Peng Fang; Peng Zhang; Fan Yang; Mei Yang; Sheng Xiao; Lijun Meng; Yan ChenShow moreShow less
1. Department of Hematology Xiangya Hospital Central South University Changsha Hunan China; 2. National Clinical Research Center for Geriatric Diseases (Xiangya Hospital) Changsha Hunan China; 3. Hunan Hematology Oncology Clinical Medical Research Center Changsha Hunan China; 4. SANO Medical Laboratories Suzhou Sano Precision Medicine Ltd Suzhou Jiangsu China; 5. Advanced Molecular Pathology Institute of Soochow University and SANO Suzhou Jiangsu ChinaShow moreShow less
Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study
Josefina Serrano; Alicia Aguirre; David Martínez‐Cuadrón; Rosa Ayala; Juan Bergua; Julio García‐Suárez; Valle Gómez‐García de Soria; Pilar Marí; Daniel García‐Belmonte; Carmen Martínez‐Chamorro; Celina Benavente; Mayte Olave; Teresa Bernal; Eduardo Rodríguez‐Arboli; Maria‐Angeles Foncillas; Lorenzo Algarra; Juan M. Alonso; Almudena Laiglesia; Esther Prados de la Torre; Montse Arnan; Carlos Rodríguez‐Medina; Rosalía Riaza; Susana Vives; Mar Tormo; Mercedes Colorado; Jorge Labrador; Olga Salamero; Cristina Gil; Raimundo García‐Boyero; Soraya Lorente; Ana Alfonso; Olga Arce; Victor Noriega; Esperanza Lavilla; Beatriz DeRueda; Laura Torres; Joaquin Sánchez‐García; Pau Montesinos; the PETHEMA GroupShow moreShow less
1. Hospital Universitario Reina Sofía‐IMIBIC UCO Córdoba Spain; 2. Hospital Universitari i Politècnic La Fe Valencia Spain; 3. Hospital Universitario 12 de Octubre Universidad Complutense Madrid Madrid Spain; 4. Hospital San Pedro Alcántara Cáceres Spain; 5. Hospital Universitario Príncipe de Asturias Madrid Spain; 6. Hospital La Princesa Madrid Spain; 7. Hospital HM Madrid CIOCC Sanchinarro Madrid Spain; 8. Hospital Universitario La Zarzuela Madrid Spain; 9. Hospital Quirón‐Pozuelo Madrid Spain; 10. Hospital Clínico San Carlos Madrid Spain; 11. Hospital Universitario Lozano Blesa Zaragoza Spain; 12. Hospital Universitario Central de Asturias Oviedo Spain; 13. Instituto de Investigación del Principado de Asturias (ISPA) Oviedo Spain; 14. Instituto Universitario de Oncología del Principado de Asturias (IUOPA) Oviedo Spain; 15. Hospital Universitario Virgen del Rocío Sevilla Spain; 16. Hospital Universitario Infanta Leonor Madrid Spain; 17. Hospital General Universitario de Albacete Albacete Spain; 18. Hospital Universitario Fundación Jiménez Díaz Madrid Spain; 19. Hospital Puerta de Hierro Madrid Spain; 20. ICO H. Hospitalet Llobregat Barcelona Spain; 21. Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas Spain; 22. Hospital Severo Ochoa Madrid Spain; 23. ICO Badalona‐Hospital Germans Trias i Pujol Josep Carreras Research Institute Barcelona Spain; 24. Hospital Clínico Universitario INCLIVA Biomedical Research Institute Valencia Spain; 25. Hospital Universitario Marqués de Valdecilla Santander Spain; 26. Hospital Universitario de Burgos Burgos Spain; 27. Hospital Universitario Vall D'Hebron Barcelona Spain; 28. Hospital General de Alicante Alicante Spain; 29. Hospital General Universitario de Castellón Castellón Spain; 30. Hospital Vithas Xanit Internacional Benalmádena Spain; 31. Clínica Universitaria de Navarra Pamplona Spain; 32. Hospital de Basurto Bilbao Spain; 33. Complejo Hospitalario Universitario A Coruña A Coruña Spain; 34. Hospital Universitario Lucus Augusti Lugo Spain; 35. Hospital Miguel Servet Zaragoza Spain; 36. Departament de Medicina Universitat de València Valencia SpainShow moreShow less
The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma
Shujun Li; Jingmin Luo; Wenjia Wei; Haiyue SunShow moreShow less
1. Department of Hematology Xiangya Hospital Central South University Changsha China; 2. National Clinical Research Center for Geriatric Diseases (Xiangya Hospital, Central South University) Changsha China; 3. Hunan Hematology Oncology Clinical Medical Research Center Changsha China; 4. Xiangya School of Medicine Central South University Changsha ChinaShow moreShow less
Baseline Spleen Volume is Independently Associated With Survival After CD19‐Directed Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
Lucas Brehm; Philipp Schindler; Christian Römer; Akhil Behringer; Valeria Carobin; Georg Evers; Cyrus Khandanpour; Julia Marx; Christian Reicherts; Jörn Albring; Matthias Stelljes; Evgenii Shumilov; Georg Lenz; Alexander PohlmannShow moreShow less
1. Department of Medicine A University Hospital Münster Münster Germany; 2. Department of Radiology University Hospital Münster Münster Germany; 3. Department of Oncology and Hematology University Hospital Oldenburg Oldenburg GermanyShow moreShow less
Adjusted Indirect Comparison Between Epcoritamab‐R 2 and Tafasitamab‐R 2 in Relapse/Refractory Follicular Lymphoma
Leonidas Benetatos; Elisavet Apostolidou; Vasileios Georgoulis; Georgios S. Markopoulos; Savvas Dimitriadis; Eleftheria Hatzimichael; Eleni KapsaliShow moreShow less
1. Department of Ηematology Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece; 2. Department of Physiology Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece; 3. Hematology Laboratory Unit of Molecular Biology and Translational Flow Cytometry University Hospital of Ioannina Ioannina GreeceShow moreShow less
FAQ
How long does HEMATOLOGICAL ONCOLOGY take to review a manuscript?
As of 2026-11-17, CrushSCI has 30 complete review records for HEMATOLOGICAL ONCOLOGY. The fastest paper went from submission to acceptance in 9 days (Characterization of Adverse Cutaneous Effects in the Setting of Ponatinib, Bosutinib, and Asciminib for Chronic Myeloid Leukemia Patients, received 2026-09-30, accepted 2026-10-09); the slowest took 359 days. The average is 172 days and the median is 174.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
